AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7861489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ungated lithotripsy at 20 to 24 kv
Number of subjects: 82
Study 7861489 — intervention group
Group type: COMPARATOR
Intervention: Gated lithotripsy
Number of subjects: 82
Study 7861489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ungated lithotripsy with pharmacological manipulation
Number of subjects: 82
Study 30375189 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine-loaded DMN (Ad-DMN) patches and topical adenosine-loaded cream (Ad-cream)
Number of subjects: 21
Study 30375189 — intervention group
Group type: COMPARATOR
Intervention: Topical adenosine-loaded cream (Ad-cream)
Number of subjects: 21
Study 28859944 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 80
Study 28859944 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 80
Study 25040544 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride mouth rinse
Number of subjects: 36
Study 25040544 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouth rinse
Number of subjects: 36
Study 25040544 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil (EO) mouth rinse
Number of subjects: 36
Study 25040544 — intervention group
Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 36
Study 24051108 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 986
Study 24051108 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 986
Study 21234793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=30) participated in three weekly group sessions followed by three weekly follow-up telephone calls over six weeks.
Number of subjects: 60
Study 21234793 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30) did not receive the intervention.
Number of subjects: 60
Study 18300284 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenserine (30 mg/day)
Number of subjects: 20
Study 18300284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18300284 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (5 mg/day)
Number of subjects: 20
Study 15988805 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time quantitative PCR
Number of subjects: 54
Study 15988805 — intervention group
Group type: COMPARATOR
Intervention: REP-PCR
Number of subjects: 54
Study 15988805 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 54
Study 12757352 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential program based on the TEACCH model
Number of subjects: 0
Study 12757352 — intervention group
Group type: EXPERIMENTAL
Intervention: TEACCH methods
Number of subjects: 0
Study 10391179 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐IGIV 1500 mg/kg
Number of subjects: 30
Study 10391179 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐IGIV 750 mg/kg
Number of subjects: 30
Study 10391179 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐IGIV 250 mg/kg
Number of subjects: 30
Study 9010611 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER (2.5 mg)
Number of subjects: 642
Study 9010611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 mg)
Number of subjects: 642
Study 9010611 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Felodipine ER 2.5 mg / Ramipril 2.5 mg)
Number of subjects: 642
Study 9010611 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 642
Study 9010611 — intervention group
Group type: COMPARATOR
Intervention: Felodipine ER monotherapy
Number of subjects: 642
Study 9010611 — intervention group
Group type: COMPARATOR
Intervention: Ramipril monotherapy
Number of subjects: 642
Study 9010611 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 642
Study 2005326 — intervention group
Group type: EXPERIMENTAL
Intervention: Local immunotherapy (LIT) with Dermatophagoides extract
Number of subjects: 22
Study 2005326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6505647 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg daily)
Number of subjects: 78
Study 6505647 — intervention group
Group type: COMPARATOR
Intervention: Control (no indomethacin)
Number of subjects: 78
Study 30475306 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized online tools and access to telephonic coaching sessions
Number of subjects: 175
Study 29537658 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sims position
Number of subjects: 120
Study 29537658 — intervention group
Group type: COMPARATOR
Intervention: Free position
Number of subjects: 120
Study 26953637 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing‐based health coaching plus a written action plan for exacerbations and brief exercise advice
Number of subjects: 215
Study 26953637 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing‐based health coaching
Number of subjects: 215
Study 26953637 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching
Number of subjects: 215
Study 26953637 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 215
Study 23821246 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic locking technique
Number of subjects: 80
Study 23821246 — intervention group
Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 80
Study 23152865 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA) and treatment instruction (TI)
Number of subjects: 41
Study 23152865 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA) and non-treatment instruction (NI)
Number of subjects: 41
Study 23152865 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA) and treatment instruction (TI)
Number of subjects: 41
Study 23152865 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA) and non-treatment instruction (NI)
Number of subjects: 41
Study 20021994 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Therapy (RPT)
Number of subjects: 63
Study 20021994 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 63
Study 18061171 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-binding protein-1
Number of subjects: 14
Study 18061171 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 14
Study 18061171 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (PBS)
Number of subjects: 14
Study 18061171 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-binding protein-1 (ex vivo)
Number of subjects: 14
Study 18061171 — intervention group
Group type: COMPARATOR
Intervention: PBS (ex vivo)
Number of subjects: 14
Study 15983299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg once daily for 12 weeks followed by 45 mg once daily for an additional 12 weeks
Number of subjects: 802
Study 15983299 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone 4 mg once daily followed by 4 mg twice daily for the same intervals
Number of subjects: 802
Study 15983299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 802
Study 15983299 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 802
Study 12464326 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (dopamine D2-receptor antagonist)
Number of subjects: 11
Study 12464326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 11
Study 10603715 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA test for IgG and IgM using glycolipid PGL-I antigen from Mycobacterium leprae
Number of subjects: 122
Study 10603715 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating immune complexes (CIC) isolated by PEG 6000 precipitation method
Number of subjects: 122
Study 10603715 — intervention group
Group type: COMPARATOR
Intervention: Comparison with tuberculosis patients
Number of subjects: 122
Study 10603715 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC antibody levels during leprosy reactions
Number of subjects: 122
Study 7860911 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (320 mg twice daily)
Number of subjects: 37
Study 7860911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 1781047 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + TAM (tamoxifen) for one year
Number of subjects: 1664
Study 1781047 — intervention group
Group type: COMPARATOR
Intervention: RT (no further therapy)
Number of subjects: 1664
Study 6109587 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg oral doses of prazosin
Number of subjects: 5
Study 6109587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30649458 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of tapentadol
Number of subjects: 24
Study 30649458 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of tramadol
Number of subjects: 24
Study 30649458 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo (calcium tablets)
Number of subjects: 24
Study 30463785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal washout with povidone‐iodine (RW‐PI)
Number of subjects: 69
Study 30463785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal washout with Ringer solution with an irrigation instrument (RW‐R)
Number of subjects: 69
Study 30463785 — intervention group
Group type: COMPARATOR
Intervention: Rectal washout with Ringer solution without an irrigation instrument (RW)
Number of subjects: 69
Study 27088462 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training at 20 Hz
Number of subjects: 45
Study 27088462 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training at 40 Hz
Number of subjects: 45
Study 27088462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibration training)
Number of subjects: 45
Study 25414931 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily
Number of subjects: 0
Study 25414931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22607748 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive feeding intervention (demonstrated five feeding interactions: hand‐washing, self‐feeding, verbal responsivity, managing refusals non‐forcefully, dietary diversity)
Number of subjects: 34
Study 22607748 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive feeding intervention
Number of subjects: 34
Study 21661456 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia
Number of subjects: 150
Study 21661456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-tenon anaesthesia
Number of subjects: 150
Study 21661456 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anaesthesia
Number of subjects: 150
Study 21661456 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study 18546051 — intervention group
Group type: EXPERIMENTAL
Intervention: Thighplasty
Number of subjects: 14
Study 16569820 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg twice daily for 10 days
Number of subjects: 20
Study 16569820 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 20
Study 12972305 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal haemoglobin group (>/=13 g/dl in males, >/=12 g/dl in females)
Number of subjects: 350
Study 12972305 — intervention group
Group type: COMPARATOR
Intervention: Anaemic group (<13 g/dl in males, <12 g/dl in females)
Number of subjects: 350
Study 12972305 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 350
Study 10548200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine infusion (0.5, 1.0, 2.0, and 4.0 microg/kg/min)
Number of subjects: 12
Study 10548200 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine infusion
Number of subjects: 12
Study 8740612 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (150 micrograms)
Number of subjects: 20
Study 8740612 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lignocaine (40 mg)
Number of subjects: 20
Study 8740612 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clonidine (150 micrograms) and lignocaine (40 mg)
Number of subjects: 20
Study 8740612 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clonidine and lignocaine
Number of subjects: 20
Study 8740612 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 20
Study 8740612 — intervention group
Group type: COMPARATOR
Intervention: All injections
Number of subjects: 20
Study 8740612 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 20
Study 1896416 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal chorionic villus sampling (TA-CVS)
Number of subjects: 1194
Study 1896416 — intervention group
Group type: COMPARATOR
Intervention: Transcervical chorionic villus sampling (TC-CVS)
Number of subjects: 1194
Study 6342863 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 32
Study 6342863 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 32
Study 6342863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30790690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 136
Study 30790690 — intervention group
Group type: COMPARATOR
Intervention: Control (oral P2Y12 inhibitors)
Number of subjects: 136
Study 29169907 — intervention group
Group type: EXPERIMENTAL
Intervention: Upside-down position
Number of subjects: 24
Study 29169907 — intervention group
Group type: COMPARATOR
Intervention: Standard Valsalva manoeuvre (VM)
Number of subjects: 24
Study 28076182 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (Learning to BREATHE program)
Number of subjects: 109
Study 26205277 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization and interventions to improve emergency obstetric and newborn care
Number of subjects: 33708
Study 26205277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33708
Study 23946346 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic index (GI) diet (GI 70)
Number of subjects: 32
Study 23946346 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% carbohydrate (CHO) intake
Number of subjects: 32
Study 23946346 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI diet
Number of subjects: 32
Study 23946346 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 32
Study 23946346 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding after CR
Number of subjects: 32
Study 23946346 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% CHO intake during refeeding
Number of subjects: 32
Study 21127451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (advanced practice nurses and psychiatric consultation‐liaison nurse)
Number of subjects: 0
Study 21127451 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (instructions on symptom management toolkit)
Number of subjects: 0
Study 18978630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic bench throw (BT) at 55% and 80% of predicted one-repetition maximum
Number of subjects: 8
Study 18978630 — intervention group
Group type: COMPARATOR
Intervention: Traditional bench press (BP) at 55% and 80% of predicted one-repetition maximum
Number of subjects: 8
Study 18978630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic bench throw (BT) at 80% of predicted one-repetition maximum
Number of subjects: 8
Study 17146153 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental candy containing beta‐conglycinin
Number of subjects: 240
Study 17146153 — intervention group
Group type: COMPARATOR
Intervention: Placebo candy containing casein
Number of subjects: 240
Study 12919177 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary medicine
Number of subjects: 0
Study 12919177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11080723 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of MSG
Number of subjects: 130
Study 11080723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 11080723 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of MSG
Number of subjects: 130
Study 11080723 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of MSG with food
Number of subjects: 130
Study 9192929 — intervention group
Group type: COMPARATOR
Intervention: General exercise training while breathing room air (GET/RA)
Number of subjects: 24
Study 9192929 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercise training while breathing supplemental oxygen (GET/O2)
Number of subjects: 24
Study 9192929 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GET/RA and GET/O2)
Number of subjects: 24
Study 9192929 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation of oxygen during training
Number of subjects: 24
Study 8445420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF) intravenously (IV), six cycles every 4 weeks
Number of subjects: 747
Study 8445420 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (Tam) 30 mg/d for 2 years
Number of subjects: 747
Study 8445420 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus cyclophosphamide (AC) intravenously, eight cycles every 3 weeks
Number of subjects: 747
Study 8445420 — intervention group
Group type: COMPARATOR
Intervention: AC plus Tam
Number of subjects: 747
Study 3885700 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone, 300 mg every 8 hours
Number of subjects: 16
Study 3885700 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide, 200 mg every 8 hours
Number of subjects: 16
Study 3885700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31287336 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART program
Number of subjects: 226
Study 31287336 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control
Number of subjects: 226
Study 30592183 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO)
Number of subjects: 47
Study 30592183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 26905433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate calcium at 1.25 mmol/l
Number of subjects: 82
Study 26905433 — intervention group
Group type: COMPARATOR
Intervention: Dialysate calcium at 1.5 mmol/l (Control)
Number of subjects: 82
Study 25242594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine devices (IUDs) - ever use
Number of subjects: 16858
Study 25242594 — intervention group
Group type: EXPERIMENTAL
Intervention: Inert IUDs
Number of subjects: 16858
Study 25242594 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at first use (≥ 35 years)
Number of subjects: 16858
Study 25242594 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at last use (≥ 45 years)
Number of subjects: 16858
Study 25242594 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of use (≥ 10 years)
Number of subjects: 16858
Study 25242594 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent use (within 1 year of study entry)
Number of subjects: 16858
Study 22235139 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 200 mg single oral dose
Number of subjects: 9
Study 22235139 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (matched, n = 9)
Number of subjects: 9
Study 19691492 — intervention group
Group type: EXPERIMENTAL
Intervention: Velusetrag 5 mg
Number of subjects: 60
Study 19691492 — intervention group
Group type: EXPERIMENTAL
Intervention: Velusetrag 15 mg
Number of subjects: 60
Study 19691492 — intervention group
Group type: EXPERIMENTAL
Intervention: Velusetrag 30 mg
Number of subjects: 60
Study 19691492 — intervention group
Group type: EXPERIMENTAL
Intervention: Velusetrag 50 mg
Number of subjects: 60
Study 19691492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18344007 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of unpasteurized milk only as a child
Number of subjects: 22808
Study 18344007 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of unpasteurized milk as a child and an adult
Number of subjects: 22808
Study 18344007 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of unpasteurized milk only as a child (adjusted for confounding factors)
Number of subjects: 22808
Study 18344007 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of unpasteurized milk as a child and an adult (adjusted for confounding factors)
Number of subjects: 22808
Study 15779882 — intervention group
Group type: EXPERIMENTAL
Intervention: Labels for two moving images
Number of subjects: 64
Study 15779882 — intervention group
Group type: EXPERIMENTAL
Intervention: Labels for two still images
Number of subjects: 64
Study 15779882 — intervention group
Group type: EXPERIMENTAL
Intervention: Three repetitions of each label
Number of subjects: 64
Study 12691269 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Listerine Antiseptic)
Number of subjects: 319
Study 12691269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental floss (Reach Dental Floss)
Number of subjects: 319
Study 12691269 — intervention group
Group type: COMPARATOR
Intervention: Negative control rinse
Number of subjects: 319
Study 10529044 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbohaler
Number of subjects: 102
Study 10529044 — intervention group
Group type: EXPERIMENTAL
Intervention: Easi-breathe
Number of subjects: 102
Study 10529044 — intervention group
Group type: COMPARATOR
Intervention: metered-dose inhaler and Volumatic
Number of subjects: 102
Study 7793216 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% sevoflurane in oxygen (n = 21)
Number of subjects: 40
Study 7793216 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane with nitrous oxide (n = 19)
Number of subjects: 40
Study 7793216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (sevoflurane in oxygen and sevoflurane with nitrous oxide)
Number of subjects: 40